Tertomotide
Grundinformationen
- CAS
915019-08-8- Standard-SMILES
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)[C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O- InChIKey
WZJRQXZSYQYFJV-QAXVQDKQSA-N- Summenformel
- C85H146N26O21
- Durchschnittliche Molmasse
- 1.868,2 g/mol
- Monoisotopische Masse
- 1.867,11558577
Überblick
Tertomotide is under investigation in clinical trial NCT01223209 (A Study, Combination, Immunologic Study of LTX-315 as adjunct to tertomotide in Patients Following Curative Surgery for Carcinoma). It is a peptide vaccine that activates the immune system so that it recognizes and kills cancer cells. It is being developed by Pharmexa A/S.
Namen und Bezeichner
- Bevorzugter Name
- Tertomotide
- IUPAC
- (2S)-6-amino-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
- Englischer Name
- Tertomotide
- Summenformel
- C85H146N26O21
- Molmasse
- 1868.23
Namen und Synonyme
TERTOMOTIDETertomotide [INN]GV-100155R7RG342O915019-08-8GV 1001tertomotidumTertomotidaPrimoVaxRefChem:896624TERTOMOTIDE [WHO-DD]GV1001
Weitere Namen anzeigen
L-Lysine, L-α-glutamyl-L-alanyl-L-arginyl-L-prolyl-L-alanyl-L-leucyl-L-leucyl-L-threonyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-prolyl-
HUMAN TELOMERASE REVERSE TRANSCRIPTASE PEPTIDE (AMINO ACID 611-626)UNII-55R7RG342OSCHEMBL29357887GLXC-21865
Datenbank-Bezeichner
- CAS
915019-08-8- PubChem CID
- 56843375
- ChEMBL
CHEMBL2108308
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- -7,6
- Polarare Oberfläche (TPSA)
- 779 Ų
- H-Brücken-Donoren
- 25
- H-Brücken-Akzeptoren
- 26
- Frei drehbare Bindungen
- 60
- Schwere Atome
- 132
- Formalladung
- 0
- Komplexität
- 3.910
Physikochemische Eigenschaften
- Dichte
- 1.427 · 1.427±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
- pka
- 3.605 · 3.605±0.21(predicted)
Chemie und Industrie
Pharmakologische Informationen
PharmacodynamicsTertomotide is a peptide vaccine that activates the immune system so that it recognises and kills cancer cells.
Mechanism of ActionTertomotide targets an enzyme called telomerase. Telomerase is seldom found in normal cell types but is overexpressed in most cancer cells.
Anbieter8 Anbieter
太原百利恒康生物技术有限公司19135651983 · [email protected]
LEON (NANJING) BIOTECHNOLOGY CO., LTD.15051830413 · [email protected]
合肥赛曼诺生物科技有限公司0551-65326643 18156095617 · [email protected]
合肥赛曼诺生物科技有限公司0551-65326643 18156095617 · [email protected]
南京莱昂生物科技有限公司025-84523390 -127; 17705183659 · [email protected]
南京肽业生物科技有限公司025-58361106-805 15951641583 · [email protected]
南京美韬医药科技有限公司[email protected] · [email protected]
成都菁临生物科技有限公司17711399154 · [email protected]
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…